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Abstract 
Background. Gliomas are composed of multiple clones of tumor cells. This intratumor 
heterogeneity contributes to the ability of gliomas to resist treatment. It is vital that gliomas 
are fully characterized at a molecular level when a diagnosis is made to maximize treatment 
effectiveness. 
Methods. We collected ultrasonic tissue fragments during glioma surgery. Large tissue 
fragments were separated in the operating theatre and bathed continuously in oxygenated 
artificial cerebrospinal fluid to keep them alive. The ex vivo tissue fragments were transferred 
to a laboratory and incubated in 5-aminolevulinic acid (5-ALA). 5-ALA is metabolised to 
Protoporphyrin IX (PpIX), which accumulates in glioma cells and makes them fluorescent.  
The molecular and neuropathological features of the PpIX fluorescent ultrasonic tissue 
fragments were studied. 
Results. We show that PpIX fluorescence can rapidly identify tissue fragments infiltrated by 
glioma in the laboratory. Ultrasonic tissue fragments from the tumor core provided molecular 
and neuropathological information about the glioma that was comparable to the surgical 
biopsy. We characterized the heterogeneity within individual gliomas by studying ultrasonic 
tissue fragments from different parts of the tumor. We found that gliomas exhibit a power 
relationship between cellular proliferation and tumor infiltration. Tissue fragments that 
deviate from this relationship may contain foci of more malignant glioma. The methylation 
status of the O6-methlguanine DNA methyltransferase (MGMT) gene promoter varied within 
each glioma.  
Conclusion. Ex vivo ultrasonic tissue fragments can be rapidly screened for glioma 
infiltration. They offer a viable platform to characterize heterogeneity within individual 
gliomas, thereby enhancing their diagnosis and treatment. 
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Key points 
• 5-ALA induced fluorescence detects glioma infiltration in ex vivo brain tissue 
• Ultrasonic tissue fragments from gliomas provide diagnostic molecular information 
• 5-ALA screened ultrasonic tissue fragments can reveal intratumoral heterogeneity  
 
 
Importance of the study 
Gliomas are comprised of multiple clones of tumor cells. This intratumor heterogeneity is a 
key factor in the ability of gliomas to resist treatment. It is vital that gliomas have a full 
molecular characterization at diagnosis to maximize treatment efficacy. We developed a rapid 
fluorescence-based screening protocol to identify glioma infiltration in ex vivo brain tissue 
fragments collected by ultrasonic aspirators. We show that brain tissue fragments provide 
molecular information that is relevant to diagnosis and treatment. We propose that ex vivo 
ultrasonic tissue fragments are a valuable resource that can be used to assess intratumoral 
heterogeneity. 
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Gliomas were originally classified according to their histopathological features. Recently, 
however, greater emphasis has been placed on the molecular profile of gliomas for diagnosis 
and prognosis.1 In parallel, precision medicine treatments of gliomas are being based on the 
molecular profiles of the glioma cells. 
 
Research studies have employed molecular profiling to show that gliomas do not have a 
uniform cellular composition, but rather are composed of multiple cell types at different 
stages of differentiation.2-5 Therefore, a neuropathological diagnosis of gliomas is most 
accurate when multiple sites within the tumor are sampled.6 This presents a problem when 
the tumor is near an eloquent area or is difficult to access surgically. 
 
Ultrasonic aspirators generate small fragments of tissue that are aspirated as they are 
produced.7 These devices can remove tumor tissue while leaving neighbouring, healthy brain 
parenchyma and blood vessels intact. This feature combined with their ease of use meant that 
they were rapidly adopted by neurosurgeons for microsurgical dissection of brain tumors.8 
 
It was quickly realised that the tissue fragments generated by ultrasonic aspirators may have 
diagnostic value. Concerns were raised that the small samples produced by ultrasonic 
aspirators may not show key histopathological features, such as necrosis, and that the process 
of fragmenting the tissue may cause artefacts.9 However, other studies of brain tumor 
samples produced by ultrasonic aspirators indicate that they recapitulate many of the 
histopathological10 and immunocytochemical11  features found in the larger samples collected 
with brain tumor biopsy forceps. Moreover, ultrasonic aspirators make it very easy to take 
samples from multiple parts of the tumor. Despite this, ultrasonic sampling of brain tumors is 
not in widespread, clinical use.  
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The ability to screen ultrasonic tissue fragments for tumor infiltration would greatly increase 
their clinical value. Fluorescence imaging has been used to detect tumor per-operatively.12-16 
We used the same approach to identify ultrasonic tissue fragments infiltrated with glioma.  
These ultrasonic tissue fragments were stored under acute conditions used by neuroscientists 
to keep brain tissue alive.17,18 We found that the ultrasonic samples recapitulated the 
molecular features of the biopsy samples that are collected routinely. Furthermore, ultrasonic 
samples taken from different parts of the glioma showed heterogeneity in the methylation 
status of the MGMT gene promoter and cellular proliferation indices. Our findings suggest 
that ultrasonic samples can play a valuable role as an adjunct to brain tumor biopsy in both 
diagnosis and planning treatment. 
 
Materials and Methods 
Ethics approval and consent to participate 
The UK Human Research Authority (https://www.hra.nhs.uk/) approved the collection of 
brain samples following a favourable opinion from the South West Research Ethics 
Committee (REC approval code: 18/SW/0022). Brain samples were donated by participants 
with a suspected diffuse astrocytic or oligodendroglial tumor1 who had not had brain surgery 
previously or received chemotherapy or radiotherapy. All participants gave informed consent 
prior to their surgery. The consent included permission to use and present their data. 
 
Intraoperative 5-ALA-induced fluorescence 
All participants were given 20 mg/kg of 5-ALA two hours prior to their craniotomy for a 
fluorescence-guided tumor resection at King’s College Hospital, London between January 
2019 and September 2019. The neurosurgeon recorded whether (s)he could see 5-ALA-
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induced fluorescence with the operating microscope (Zeiss OPMI Pentero 900 or Zeiss 
KINEVO 900 operating microscope) during the surgery.  
 
Intraoperative sample collection 
Ultrasonic samples were collected during surgery with a Sonopet ultrasonic aspirator (Stryker 
Corp, MI, USA) with an angled handpiece and straight, soft tissue tip (outer diameter 1.92 
mm, inner diameter 1.50 mm) oscillating at 25 kHz. Tissue fragments were collected with the 
following console settings: aspiration 5 - 10%, power 5 - 10% and irrigation 5 - 10%. The 
anatomical location of the tissue samples was documented with either the intraoperative 
surgical navigation system (Stealth S7 or S8, Medtronic, Minneapolis, USA) or intraoperative 
ultrasound (ESAOTE), combined with intraoperative images (Zeiss OPMI Pentero 900 or 
Zeiss KINEVO 900 operating microscope) of the exposed brain (Figure 1A, B). The tissue 
fragments were collected in a specimen trap (Pennine, MST-3070) connected to the Sonopet 
aspiration system (Figure 1C). The tumor biopsy was given preference when tissue was 
collected as the tumor biopsy was used for diagnosis and the ultrasonic samples were not. 
 
The operating surgeon co-ordinated collection of the ultrasonic samples to ensure tumor 
samples from known locations were sampled. When the specimen trap was filled, the 
contents were passed through a nylon mesh to separate larger tissue fragments from the 
smaller fragments. The larger fragments were rinsed with cerebrospinal fluid (CSF) that had 
been modified to prevent neural firing and excitoxicity.19 The transportation CSF comprised 
(in mM): 108 choline-Cl, 3 KCl, 26 NaHCO3, 1.25 NaHPO4, 25 D-glucose, 3 Na pyruvate, 2 
CaCl2, 1 MgCl2 and 1 Heparin, which had been cooled to 4
 C and bubbled with 95% 
Oxygen / 5% CO2. The large tissue fragments were then transferred to a ex vivo tissue 
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transportation system, which keeps the tissue fragments cool while bathing them in 
transportation CSF.20 
 
After arriving in the laboratory, the ultrasonic samples were transferred to an incubation 
chamber. The artificial CSF used for the incubation chamber was changed to (mM): 120 
NaCl, 3 KCl, 23 NaHCO3, 1.25 NaHPO4, 10 D-glucose, 2 CaCl2, and 1 MgCl2 bubbled with 
95% Oxygen / 5% CO2. The artificial CSF was gradually warmed to 37 C. The larger 
fragments were imaged and then processed for a neuropathological and molecular diagnosis 
(Figure 1D – F). 
  
Ex vivo imaging 
PpIX photobleaches quickly.21 This makes it harder to see low levels of PpIX fluorescence 
with an operating microscope. Therefore, we stored ex vivo ultrasonic tissue fragments in a 
low volume incubation chamber (Scientific Systems Design, Ontario, Canada) and bathed the 
tissue fragments in 1 mM 5-ALA (Sigma: 5451-09-2) for thirty minutes prior to experiments, 
which was continued during experiments.21 
 
The ultrasonic samples were imaged on an interface recording chamber22 (Scientific Systems 
Design, Ontario, Canada), which was mounted on an Olympus BX51WI epifluorescence 
microscope. A custom filter set (excitation 402/15 nm, emission 654/75 nm; Chroma 
Technology Corp, VT, USA) was fitted to the filter cube turret of the BX51WI microscope to 
detect PpIX fluorescence. The laboratory fluorescence images and brightfield images were 
acquired on a Spot RT sCMOS cooled 5MP camera (RT39M5, Spot Imaging, USA) 
controlled by Spot Advanced imaging software (Spot Imaging, USA).  
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The fluorescence signal was quantified in FIJI (https://imagej.net/Fiji).23 The mean pixel 
intensity of the background (no tissue) was subtracted from pixel intensity in the tissue 
fragment region of interest. The pixel intensities in the region of interest were summed and 
divided by the area of the region of interest to give a total fluorescence signal x 107 per mm2, 
which is expressed in relative fluorescence units (RFU).  
 
Neuropathological processing 
Ex vivo ultrasonic samples from the edge and core of high-grade gliomas were imaged in the 
laboratory in five participants. Both the core and edge samples were then processed 
histologically for tumor markers. The tissue fragments were fixed in 10% formalin and 
embedded in paraffin blocks. 4 - 5 µm sections were cut for immunohistochemistry. 
Immunohistochemistry, diagnostic genetic testing and neuropathological assessment of brain 
tumors were performed by the Department of Clinical Neuropathology, King’s College 
Hospital, which is accredited by the United Kingdom Accreditation System and works in 
accordance with ISO standards 15189 for medical laboratories.  
 
Neuropathology slides were imaged on an Olympus Slide scanner VS120. The images were 
analysed with FIJI software (https://imagej.net/Fiji). A circularity and size filter were applied 
to the identified objects in the image. The filter parameters were adjusted to select rounded 
tumor cells and to discard nestin-positive endothelial cells, which were more elongated. The 
methylation status of the MGMT gene promoter at four CpG sites was determined by 
pyrosequencing using the therascreen MGMT pyro kit (Qiagen, Hilden, Germany). 
 
Statistical analysis 
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Graph Pad Prism 8 was used for statistical analysis and graphing. Normally-distributed data 
were described by their mean ± standard error. The linear regression function was used to fit 
lines to data. Statistical tests were two-tailed and had a threshold for type 1 statistical error of 
α < 0.05. Means were compared with t-tests or a repeated measures ANOVA (MGMT gene 
promoter methylation) if the data fulfilled the assumptions for parametric tests. A Mann-
Whitney U-test was used when parametric tests were not appropriate. The power relationship 
between cell proliferation, measured by the density of Ki-67 positive nuclei, and tumor 
infiltration was assumed to be: 
Ki-67 positive nuclei = k(tumor infiltration)n  
where k is a constant and n is the power value.  The data were plotted in the log – log format 
(Figure 4F) so that the slope of the line estimates the power, n, and the intercept with the x-
axis when log Ki-67 positive nuclei equals zero (dashed line Figure 4F) gives a measure of 
the number of tumor cells that are present when one cell is proliferating. 
 
Results 
The presence of glioma cells in the screened ultrasonic tissue fragments was confirmed with 
histochemical stains and immunocytochemical stains against brain tumor markers (Figure 1).  
 
Ultrasonic tissue fragments exhibit histopathological features of gliomas 
The World Health Organization (WHO) grading of brain tumors is based on the 
histopathological and the molecular features of the tumors.1 We first investigated the 
histopathological features that were exhibited by ultrasonic tissue fragments from WHO 
grade III – IV gliomas. A consultant neuropathologist (IB) examined the ultrasonic tissue 
fragments for histopathological features of cell division (mitotic figures), vascular 
proliferation, necrosis and presence of pleomorphic cells or gemistocytes and compared the 
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findings with the results from the tumor biopsy. The probability of the ultrasonic samples 
exhibiting a histopathological feature found in the tumor biopsy was 0.33 – 1.0 (n = 7 
gliomas; Figure 2A, Table 1). 
 
We found that a tumor diagnosis could be made from the histopathological features exhibited 
by the ultrasonic samples in 6/7 cases. In one case, there were too few glioma cells in the 
ultrasonic samples to reach a diagnosis. We concluded that large ultrasonic tissue fragments 
could give histopathological information about the tumor if the tissue fragments were taken 
from the body of the tumor and avoided large areas of necrosis as reported previously.9,10,24 
 
Molecular markers in ultrasonic tissue fragments 
Molecular markers have become increasingly important to the diagnosis and management of 
gliomas.1 We asked whether ultrasonic tissue fragments provided quantifiable information 
about molecular markers.  We first investigated markers of cellular proliferation in the 
ultrasonic samples by studying expression of the Ki-67 protein in the nucleus (Figure 1E). 
We found that percentage of cells expressing Ki-67 in the ultrasonic samples from the tumor 
core was within 7.9 ± 4.0 % (n = 6 gliomas) of the Ki-67 expression in the tumor biopsy 
(Figure 2B, C).  
 
We next studied the methylation status of the promoter region of the MGMT gene. The 
MGMT protein is important therapeutically because it removes the alkyl groups on guanine 
bases that are added by the chemotherapy drug, temozolomide. Methylation of the CpG 
dinucleotides in the promoter of the MGMT gene reduces expression of the MGMT protein, 
which enhances the cytotoxicity of temozolomide. The average percentage methylation of the 
MGMT gene promoter in the ultrasonic tissue fragments taken from the core of the tumor 
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were comparable to the values for the diagnostic biopsy (mean percentage difference 1.5 ± 
0.6 %, n = 5 gliomas; Figure 2B, C). We concluded that ultrasonic samples can provide 
quantifiable information about molecular markers relevant to the diagnosis and management 
of gliomas. 
 
Fluorescence imaging to screen ex vivo ultrasonic tissue fragments for glioma infiltration 
PpIX fluorescence was seen intraoperatively with the operating microscope in 4/7 
participants (0/1 WHO grade II, 1/3 WHO grade III, 3/3 WHO grade IV; Table 2). PpIX 
fluorescence was seen in the ultrasonic samples from 6/7 participants. In one participant with 
an anaplastic oligodendroglioma (case G, Table 2), no fluorescence was seen intraoperatively 
or during screening of ultrasonic samples. In this case, very few glioma cells were present in 
the ultrasonic samples. We concluded that screening of ultrasonic tissue fragments with PpIX 
can detect infiltration by high-grade glioma cells at lower levels than seen during surgery. 
 
We next explored whether ultrasonic samples could contribute to the evaluation of 
heterogeneity within a glioma. Histopathological screening for tumor infiltration in each 
fragment before molecular analysis would not be sustainable due to the large number of 
fragments collected during the surgery. Therefore, we developed a method to screen ex vivo 
ultrasonic tissue fragments for glioma infiltration using fluorescence imaging (Materials and 
Methods). 
 
We took advantage of the 5-ALA induced fluorescence that is used by neurosurgeons to 
image WHO grade III - IV gliomas during surgery.15 5-ALA is metabolized in cells to 
Protoporphyrin IX (PpIX), which accumulates in glioma cells and causes them to be 
fluorescent (Figure 3A, B). For tumors exhibiting PpIX fluorescence during surgery, the core 
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was defined as a brain region where a fluorescence signal was visible with the operating 
microscope whereas the tumor edge exhibited no fluorescence (Figure 3B, C; Materials and 
Methods). 
 
PpIX fluorescent cells could be seen in ex vivo ultrasonic tissue fragments taken from the 
tumor edge. The relative PpIX fluorescence emitted by ex vivo ultrasonic tissue fragments 
from the tumor core was higher than from the tumor edge (mean relative PpIX fluorescence: 
core = 8.0 ± 1.3 RFU, n = 4; edge = 2.5 ± 0.9 RFU, n = 5; p = 0.010, t-test; Figure 3D – F). 
 
We calculated a second, separate immunocytochemical measure of tumor infiltration by 
quantifying high-grade glioma cells that were positive for either nestin or for IDH1 (R132H) 
mutant protein at the core and tumor edge (Figure 4A, B). Ultrasonic tissue fragments from 
the core of the tumor had a higher density of glioma cells than the edge (core = 2512 
cells.mm-2, edge = 200 cells.mm-2, n = 4 gliomas, p = 0.015 paired t-test; Figure 4B, data 
logged for presentation). 
 
We then compared the relationship between relative PpIX fluorescence imaging and tumor 
infiltration measured immunocytochemically. There was not a tight relationship between the 
relative PpIX fluorescence signal and the extent of tumor infiltration (R2 = 0.28, p = 0.18, n = 
8; Figure 4C). We explored this further by studying the spatial distribution of PpIX 
fluorescent cells. The tumor core was densely labelled with PpIX fluorescent cells (Figure 
4D). At the tumor edge, the PpIX fluorescent cells were not evenly distributed, but, were 
frequently found clustered together (Figure 4D).  
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We concluded that ex vivo ultrasonic tissue fragments could be screened for tumor infiltration 
with fluorescence imaging. The screening can be done rapidly because the tissue fragments 
do not need resectioning. The tendency for PpIX fluorescent cells to form small cell clusters 
made it easier to detect low levels of tumor infiltration at the tumor edge. 
 
Ex vivo ultrasonic samples to assess tumor heterogeneity 
The ex vivo ultrasonic tissue fragments exhibiting PpIX fluorescence were used to study 
heterogeneity within high-grade gliomas.   
 
We first asked whether ex vivo ultrasonic tissue fragments gave information on variability in 
cell proliferation in different parts of the high-grade gliomas. We stained ex vivo ultrasonic 
samples from different parts of a tumor for Ki-67 to measure cell proliferation (Figure 4E) 
and immunocytochemical tumor markers to quantify tumor infiltration. We found that cell 
proliferation, measured by the density of Ki-67 positive nuclei, had a power relationship with 
tumor infiltration for each glioma (Figure 4F; Materials and Methods). The power values for 
high-grade gliomas (WHO grade III – IV) ranged from 0.7 – 1.4 (Figure 4F). The lines from 
the more aggressive glioblastomas were to the left of the anaplastic astrocytomas (Figure 4F) 
 
Next, we focused on the methylation status of the MGMT gene promoter. The mean value for 
the methylation status of ex vivo ultrasonic tissue fragments from the core was similar to the 
values for the surgical biopsy (surgical biopsy = 15.3%, ex vivo ultrasonic samples, core = 
15.5%, edge = 3.9%; repeated measures ANOVA, p = 0.069) (Figure 4G). However, we 
found differences of up to 3.6%, which may be important in borderline cases (Figure 4G). 
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We concluded that ex vivo ultrasonic tissue fragments can capture variability in molecular 
markers, such as MGMT gene promoter methylation in the tumor core. Hence, ultrasonic 
tissue fragments can add to the surgical biopsy by giving information about tumor 
heterogeneity.  
 
Discussion 
We investigated whether ex vivo ultrasonic samples of brain tissue can facilitate the diagnosis 
and treatment of gliomas. We show that large ex vivo ultrasonic tissue fragments can be 
screened rapidly with fluorescence imaging to detect tissue fragments infiltrated with tumor. 
These tumor-infiltrated tissue fragments give detailed information about the molecular 
features of the tumor. This molecular information can be obtained either with 
immunocytochemical stains or through genetic sequencing. Importantly, ultrasonic tissue 
fragments give quantifiable data. Therefore, they can be used to characterize heterogeneity 
within a glioma. Consequently, ultrasonic samples can play a valuable role as an adjunct to 
brain tumor biopsy in both diagnosis and planning treatment.  
 
Molecular profiling of ultrasonic tissue fragments would be easy to implement if there was a 
simple way to screen the tissue fragments for tumor infiltration. Fluorescence screening is the 
option we pursued. Ideally, the fluorescent label would only be expressed in glioma cells. 
One strategy is to use fluorophores that are actively concentrated within glioma cells. 
Therefore, we stored ultrasonic tissue fragments under ex vivo conditions to keep the brain 
tissue alive.17,18 We found that increased levels of PpIX in glioma cells can be used to detect 
tumor infiltration in ex vivo ultrasonic samples.  
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Tumor recurrence is a major problem in the management of brain tumors. A key issue is 
intratumor heterogeneity.2,3,5 The heterogeneity can be captured by collecting ultrasonic 
samples from different parts of the tumor.25 We found that individual gliomas manifested a 
power relationship between cellular proliferation, measured by Ki-67 expression, and tumor 
infiltration (Figure 4F). Higher-grade tumors showed greater cellular proliferation indices. 
Points above the line for a tumor indicate foci of higher than expected proliferation within the 
tumor and may serve as an early indicator of more malignant tumor behaviour. The brain 
location of the tissue fragments can be recorded with the surgical neuronavigation system. 
Therefore, the collection site of tissue fragments with unexpectedly high proliferation indices 
can be identified. This information may be useful when planning treatment, such as 
radiotherapy. 
 
The methylation status of the MGMT gene promoter is used to predict the response of 
gliomas to alkylating chemotherapy agents.26 Heterogeneity in the methylation status of 
tumor cells within individual gliomas has been described.27,28 The extent of heterogeneity in 
MGMT gene promoter methylation within gliomas requires further evaluation. It may be 
affected by several factors including the number of glioma cell clones in the tumor, tumor 
microenvironment and developmental status of individual glioma cells. We found that 
screened ultrasonic tissue fragments capture the intratumoral heterogeneity. Notably, the 
MGMT gene promoter methylation in one of four participants was higher than reported from 
the surgical biopsy (Figure 4G). Hence, information from the ultrasonic tissue fragments 
gives a broader overview of methylation status within the tumor and may affect treatment 
decisions in cases of borderline methylation status.  
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Research studies have used the fluid from ultrasonic aspirators as a source of glioma cells for 
culturing and xenotransplantation into mice.25,29,30 Commonly, larger tissue fragments have 
been dissociated prior to culturing.25  Contamination of these cultures with healthy cells has 
been a concern in therapy studies.30 Fluorescence screening reduces this problem. Going 
forwards, screened ex vivo fragments could be used directly in research involving 3D glioma 
models rather than being dissociated first. 
 
The diagnosis and management of brain tumors is increasingly determined by the molecular 
profile of the tumor. This trend is accelerating. Tissue fragments from ultrasonic aspirators 
provide valuable molecular information that aids diagnosis. Treatment of brain tumors will 
increasingly be guided by actionable mutations in the tumor. Live ultrasonic tissue fragments 
are an underused source of tumor tissue that have great potential to improve how patients are 
diagnosed and treated. 
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Figure legends 
Figure 1 Collection and staining of large ex vivo ultrasonic tissue fragments (UTFs) 
A – F, data from participant A only. A) T2-weighted MRI of low-grade glioma in left insula. 
B) Surgical aspiration of UTFs. C) Trap for UTF collection in situ. D) Brightfield image, 
H&E stained sections of UTFs. E) Sections from one UTF in panel D stained for H&E, Ki-
67, IDH1 (R132H) mutation and NeuN. F) Higher magnification images of H&E (top) and 
IDH1 (R132H) mutation (bottom) sections shown in panel E.     
 
Figure 2 Surgical biopsy compared with ex vivo tumor-core ultrasonic tissue fragments 
from the same gliomas 
A) Glioma histopathology features found in surgical biopsies compared with tumor-core 
UTFs. B) Comparison of the results from the surgical biopsy and tumor-core UTFs for 
percentage of cells expressing nuclear Ki-67 staining and for percentage methylation of 
MGMT gene promoter (MGMTp) levels analysed from individual gliomas. C) Mean absolute 
percentage difference in Ki-67 and MGMTp methylation between the surgical biopsy and 
tumor-core UTFs for each participant. Error bars denote standard error of the mean. 
 
Figure 3 Screening for glioma infiltration in ex vivo ultrasonic tissue fragments with 
PpIX fluorescence  
A – E, data from one participant. A) Contrast enhanced T1-weighted and FLAIR MRI scans 
showing a contrast enhancing lesion in the anterior right temporal lobe. B) Intraoperative 
brain surface images (right, brightfield; left, PpIX fluorescence) of tumor edge (top panels) 
and tumor core (bottom panels). C) H&E (left panels) and Nestin (right panels) staining of 
sections through UTFs collected from the tumor edge (upper panels) and the tumor core 
(lower panels) showing marked glioma infiltration in the tumor core UTFs and sparse glioma 
NOA-D-19-00100R1    21 
 
infiltration of the tumor-edge UTFs. D) Brightfield images (left panels) and PpIX 
fluorescence images (right panels) of ex vivo UTFs from tumor edge (top panels) and tumor 
core (bottom panels). E) Relative PpIX fluorescence from the tumor edge (n = 3 UTFs, mean 
1.6 RFU) and tumor core (n = 3 UTFs, mean 8.5 RFU; p = 0.062, paired t-test) of one glioma. 
F) Mean relative PpIX fluorescence from UTFs collected from the tumor edge (n = 5 
gliomas) and tumor core (n = 4 gliomas) (p = 0.01, t-test).  
 
Figure 4 Heterogeneity of cell proliferation and MGMTp methylation of gliomas 
A) Immunocytochemically-labelled glioma cells identified using a circularity filter. Top 
panel, image (x20) of nestin stained section. Lower panel, Cell bodies of nestin-positive cells 
labelled in black after analysis. B) Density of tumor infiltration in UTFs from the edge and 
core of gliomas that were either nestin positive or IDH1 (R132H) mutation positive (n = 4 
gliomas; p = 0.04, paired t-test). C) Relationship between mean PpIX relative fluorescence 
and mean tumor infiltration of UTFs collected from tumor core and edge (n = 4 gliomas, r2 = 
0.28, p = 0.18). D) Clustering of cells exhibiting PpIX fluorescence in ex vivo UTFs from the 
tumor edge and core. E) Variation in Ki-67 positive cells in different UTFs from one 
participant. F) Plot showing power relationship between density of Ki-67 positive cells and 
tumor infiltration. Data from UTFs collected from four gliomas (slope for glioma: A = 1.2, r2 
= 0.96, p < 0.001; C = 1.4, r2 = 0.79, p = 0.018; F = 1.4, r2 = 0.34, p = 0.17;  G = 0.72, r2 = 
0.90, p = 0.06). G) Variation in methylation status of the MGMT gene promoter from the 
four gliomas in L. UTFs from tumor edge and core are compared with the surgical biopsy. 
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Table 1 Neuropathological comparison of ultrasonic tissue fragments and surgical 
biopsy 
 
 
 
 
  
 
Neuropathology - WHO features 
Ultrasonic tissue fragments 
(UTFs) 
Biopsy 
A 
•  No microvascular proliferation •  Perineuronal satelitosis 
•  No mitotic figures •  No endothelial hyperplasia 
•  No necrosis  •  No necrosis 
B 
•  Mitotic activity •  High mitotic activity 
•  Microvascular proliferation •  Microvascular proliferation  
•  No necrosis •  Apoptotic bodies 
 •  Pseudo-palisading necrosis 
C 
•  Mitotic activity •  Mitotic activity 
•  Microvascular proliferation •  Microvascular proliferation 
•  Necrosis •  Necrosis 
D 
•  Pleomorphic spindles 
•  No mitotic activity 
•  Pleomorphic spindles 
•  Mitotic activity 
•  No microvascular proliferation •  Microvascular proliferation 
  
E 
•  Gemistocytic cells •  Gemistocytic cells 
•  No mitotic activity •  Occasional Mitotic activity 
•  No microvascular proliferation 
•  No necrosis 
•  No microvascular proliferation 
•  No necrosis 
F 
•  Necrosis •  Necrosis 
•  Pleomorphic cells •  Pleomorphic cells 
•  No microvascular proliferation •  Microvascular proliferation 
•  No mitotic activity •  No mitotic activity 
G 
•  No necrosis •  No necrosis 
•  Pleomorphic cells •  Pleomorphic cells 
•  No microvascular proliferation •  Perinuclear halo formation 
•  No mitotic activity •  mitotic activity 
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Table 2 Clinical information 
 
Age 
(yrs) 
Sex Classification Location 
Intraoperative PpIX 
fluorescence 
A 27 F 
Oligodendroglioma, 
IDH1-mutant, grade II 
Left Frontal/Insula Negative 
B 62 M 
Glioblastoma, IDH 
wildtype, grade IV 
Right Temporal Positive 
C 72 M 
Glioblastoma, IDH 
wildtype, grade IV 
Left Parietal Positive 
D 29 F 
Astrocytoma, IDH1-
mutant, grade III 
Left Parietal Positive 
E 71 F 
Astrocytoma, IDH1-
mutant, grade III 
Right Temporal Negative 
F 64 M 
Glioblastoma, IDH 
wildtype, grade IV 
Right Temporal Positive 
G 71 M 
Oligodendroglioma, 
IDH1-mutant, grade III 
Right Frontal Negative 
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Figure 2 
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Figure 3 
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Figure 4 
 
 
 
 
 
